Comment on "Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease".
Jonas
J
Hannestad
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D015283:Citalopram / Q000494:pharmacology*; D004660:Encephalitis / Q000517:prevention & control; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000517:prevention & control*; D008070:Lipopolysaccharides / Q000009:adverse effects*; D051379:Mice; D009410:Nerve Degeneration / Q000517:prevention & control; D009474:Neurons / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000473:pathology; D017374:Paroxetine / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D015283:Citalopram; D008070:Lipopolysaccharides; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors